1. ScholarBank@NUS
  2. 1. Staff
  3. Staff Publications
Please use this identifier to cite or link to this item: https://doi.org/10.3389/fmicb.2018.01612
DC FieldValue
dc.titleImmunomodulation as therapy for fungal infection: Are we closer?
dc.contributor.authorSam, Q.H.
dc.contributor.authorYew, W.S.
dc.contributor.authorSeneviratne, C.J.
dc.contributor.authorChang, M.W.
dc.contributor.authorChai, L.Y.A.
dc.date.accessioned2020-09-07T05:05:10Z
dc.date.available2020-09-07T05:05:10Z
dc.date.issued2018
dc.identifier.citationSam, Q.H., Yew, W.S., Seneviratne, C.J., Chang, M.W., Chai, L.Y.A. (2018). Immunomodulation as therapy for fungal infection: Are we closer?. Frontiers in Microbiology 9 (JUL) : 1612. ScholarBank@NUS Repository. https://doi.org/10.3389/fmicb.2018.01612
dc.identifier.issn1664302X
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/174534
dc.description.abstractInvasive fungal disease (IFD) causes significant morbidity in immunocompromised patients due to their weakened immune system. Immunomodulatory therapy, in synergy with existing antifungal therapy, is an attractive option to enhance their immune system and aid clearance of these opportunistic pathogens. From a scientific and clinical perspective, we explore the immunotherapeutic options to augment standard antifungal drugs for patients with an IFD. We discuss the range of immunomodulatory therapies being considered in IFD - from cytokines, including G-CSF, GM-CSF, M-CSF, IFN-?, and cytokine agonists, to cellular therapies, consisting of granulocyte transfusion, adoptive T-cell, CAR T-cell, natural killer cell therapies, and monoclonal antibodies. Adjunct pharmaceutical agents which augment the immunity are also being considered. Lastly, we explore the likelihood of the use of probiotics and manipulation of the microbiome/mycobiome to enhance IFD treatment outcomes. © 2018 Sam, Yew, Seneviratne, Chang and Chai.
dc.publisherFrontiers Media S.A.
dc.sourceUnpaywall 20200831
dc.subjectauranofin
dc.subjectcolony stimulating factor 1
dc.subjectcytokine receptor agonist
dc.subjectdeferasirox
dc.subjectebselen
dc.subjectefungumab
dc.subjectgamma interferon
dc.subjectgranulocyte colony stimulating factor
dc.subjectgranulocyte macrophage colony stimulating factor
dc.subjectinterleukin 12p40
dc.subjectinterleukin 6
dc.subjectmolgramostim
dc.subjectprobiotic agent
dc.subjectrecombinant gamma interferon
dc.subjectrecombinant granulocyte macrophage colony stimulating factor
dc.subjectretinol
dc.subjectsargramostim
dc.subjectsuppressor of cytokine signaling 3
dc.subjecttamoxifen
dc.subjecttoll like receptor 9
dc.subjecttoll like receptor agonist
dc.subjecttumor necrosis factor
dc.subjectvitamin D
dc.subjectadoptive T cell therapy
dc.subjectantifungal therapy
dc.subjectcell therapy
dc.subjectchimeric antigen receptor natural killer cell immunotherapy
dc.subjectchimeric antigen receptor T-cell immunotherapy
dc.subjectclinical trial (topic)
dc.subjectcryptococcal meningitis
dc.subjectcryptococcosis
dc.subjectCryptococcus neoformans
dc.subjectdrug repositioning
dc.subjectgranulocyte transfusion
dc.subjecthuman
dc.subjectimmunomodulation
dc.subjectmicrobiome
dc.subjectnonhuman
dc.subjectphase 1 clinical trial (topic)
dc.subjectphase 2 clinical trial (topic)
dc.subjectReview
dc.subjectsystemic mycosis
dc.subjectT lymphocyte
dc.typeReview
dc.contributor.departmentBIOCHEMISTRY
dc.contributor.departmentDENTISTRY
dc.contributor.departmentMEDICINE
dc.description.doi10.3389/fmicb.2018.01612
dc.description.sourcetitleFrontiers in Microbiology
dc.description.volume9
dc.description.issueJUL
dc.description.page1612
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3389_fmicb_2018_01612.pdf815.22 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.